Clinical trials · Ohio
Lymphoma clinical trials in Ohio
We’re tracking 130 recruiting lymphoma studies with a site in Ohio — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Ohio
- NCT04771572RecruitingPhase 1
Oral drug LP-118 for relapsed blood cancers
This Phase 1 study tests an oral (by mouth) drug called LP-118 in people whose blood cancers have returned or did not respond to prior treatment. The goal is to find a safe dose and see whether it can shrink or control the cancer.
Cincinnati, OhioAges 13 years+ - NCT04570423RecruitingPhase 2
Eflapegrastim safety study for children and teens on chemo
This trial studies how safe eflapegrastim is in pediatric patients with certain solid tumors or lymphomas who are starting chemotherapy that lowers white blood cells. It also looks at how the medicine behaves in the body to help reduce the risk of dangerous infections.
Cleveland, OhioAges 1 month–17 years - NCT03719105RecruitingEarly Phase 1
Chemo plus immunotherapy with donor stem cell transplant for NK lymphoma
This early-phase study tests a combination treatment—chemo, immunotherapy, and a donor stem cell transplant—for certain aggressive NK/T-cell lymphomas. It may help patients who have advanced-stage disease by trying to improve long-term control of the cancer.
Columbus, OhioAges 1–31 - NCT03681561RecruitingPhase 1/Phase 2
Nivolumab plus ruxolitinib for relapsed Hodgkin lymphoma
This trial tests nivolumab (an immune therapy) combined with ruxolitinib (a drug that targets immune signaling) for people whose classical Hodgkin lymphoma has come back or did not respond. It may help shrink the lymphoma and improve disease control after prior treatments, including checkpoint inhibitor therapy.
Columbus, OhioAges 18 years+ - NCT03523975RecruitingPhase 1/Phase 2
Testing venetoclax, lenalidomide, and rituximab for new mantle cell lymphoma
This early-phase study tests a combination of venetoclax, lenalidomide, and rituximab in people newly diagnosed with mantle cell lymphoma. It aims to control the lymphoma and see how safe and effective this approach is for newly treated patients.
Columbus, OhioAges 18 years+ - NCT01351545Recruiting
Cryopreserved cord blood access program for transplant patients
This trial studies an organized way to obtain and distribute unlicensed (not FDA-approved for general use) stored cord blood units that have been frozen and kept. It may help people who need a cord blood transplant but don’t fit the “licensed cord blood only” options.
Akron, OhioAges Any age - NCT00900198Recruiting
Give cancer tissue samples to help future cancer research
This study collects tissue or other cancer-related samples to help researchers better understand cancer and develop better tests or treatments. You can join if you are being evaluated for or treated for cancer, and you agree to let your samples be used for research.
Columbus, OhioAges 2 months+ - NCT06717347RecruitingPhase 3
Study of a new drug combo for untreated DLBCL
This trial tests whether adding zilovertamab vedotin to standard chemo (R-CHP) works better than standard chemo (R-CHOP) for people with untreated diffuse large B-cell lymphoma (DLBCL). It aims to find a more effective treatment option.
Cincinnati, OhioAges 18 years+ - NCT07685717RecruitingPhase 2
Pirtobrutinib for older adults with CLL
This trial tests a new pill, pirtobrutinib, for people 75 or older with chronic lymphocytic leukemia (CLL) who have never had treatment before. The goal is to see if it helps control the disease with manageable side effects.
Columbus, OhioAges 75 years+ - NCT07342478RecruitingPhase 3
Comparing two BTK inhibitors for CLL/SLL after prior treatment
This study compares two oral targeted therapies, rocbrutinib and pirtobrutinib, for people with CLL or SLL whose disease has come back or stopped responding after treatment with a covalent BTK inhibitor (like ibrutinib). The goal is to see which drug works better and has fewer side effects.
Columbus, OhioAges 18 years+ - NCT07192471RecruitingPhase 1
Study of KK2223 for T-cell lymphoma after prior treatments
This study tests a new drug called KK2223 for people with certain types of T-cell lymphoma (PTCL or CTCL) that have not responded to previous treatments. The goal is to find out if the drug is safe and if it helps shrink or control the lymphoma.
Cleveland, OhioAges 18 years+ - NCT07154823Recruiting
Blood cancer registry study for biomarker discovery
This study collects samples and health information from people with certain blood cancers to learn more about the disease and find markers that may help guide future treatments. You will not receive a treatment from this study, but you may help advance research.
Cincinnati, OhioAges birth+ - NCT07014917RecruitingPhase 2
Comparing two ways to take venetoclax and acalabrutinib for CLL/SLL
This trial tests whether taking venetoclax on an intermittent schedule (not every day) works as well as taking it continuously when combined with acalabrutinib for people with untreated CLL or SLL. It aims to find a treatment approach that might be just as effective but with fewer side effects.
Cincinnati, OhioAges 18 years+ - NCT06876649RecruitingPhase 4
Long-term safety study of Pirtobrutinib
This trial is for people who are already in a Lilly study taking pirtobrutinib. It looks at the long-term safety of the drug by continuing to monitor you.
Columbus, OhioAges 18 years+ - NCT06846671RecruitingPhase 3
Study of a new drug for CLL or SLL
This trial tests a new investigational drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already tried two types of treatments (BTK and BCL2 inhibitors). The goal is to see if this new drug works better than other available treatments chosen by the doctor.
Cleveland, OhioAges 18 years+ - NCT06765109RecruitingPhase 3
Testing neladalkib for untreated ALK-positive lung cancer
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
Cincinnati, OhioAges 18 years+ - NCT06678659RecruitingPhase 1/Phase 2
Study of REC-1245 for advanced solid tumors and lymphoma
This trial tests a new drug, REC-1245, for people with advanced solid tumors or certain lymphomas that have not responded to standard treatments. The goal is to see if the drug can shrink tumors or slow disease progression.
Cleveland, OhioAges 12 years+ - NCT06672705RecruitingPhase 1
Epcoritamab for lymphoma that returns after an organ transplant
This study tests a drug called epcoritamab for people who have a type of lymphoma that developed after an organ transplant and has not responded to standard treatment. The drug aims to help your immune system fight the cancer cells.
Columbus, OhioAges 18 years+ - NCT06500273RecruitingPhase 2
Cema-cel for high-risk lymphoma after first treatment
This trial tests a new treatment called cema-cel for people with large B-cell lymphoma who are in remission after first-line therapy but still have tiny amounts of cancer detected by a sensitive blood test. The goal is to prevent the cancer from coming back.
Cincinnati, OhioAges 18 years+ - NCT06466122RecruitingPhase 2
Pirtobrutinib plus Venetoclax for resistant CLL or SLL
This trial tests two oral targeted drugs—pirtobrutinib and venetoclax—for people with CLL or SLL whose disease has continued to grow despite taking a BTK inhibitor (such as ibrutinib, acalabrutinib, or zanubrutinib). The goal is to see if this combination can control the cancer when a BTK inhibitor alone is no longer working.
Columbus, OhioAges 18 years+ - NCT06441331RecruitingPhase 1
Lu-177 edotreotide for children with SSTR-positive tumors
This trial tests a radioactive drug called Lu-177 edotreotide for children with a certain type of tumor (SSTR-positive) that hasn't responded to other treatments. The goal is to find the right dose and see how safe it is.
Cincinnati, OhioAges 2–18 - NCT06447376RecruitingPhase 1
Testing siltuximab before epcoritamab to prevent cytokine release syndrome
This trial tests whether giving siltuximab before epcoritamab can help prevent or reduce cytokine release syndrome (a possible side effect where the immune system overreacts). It is for people with certain types of non-Hodgkin lymphoma that have not responded well to at least two prior treatments.
Cleveland, OhioAges 18–65 - NCT06418204Recruiting
Cannabis use among cancer patients in community clinics
This study looks at how cancer patients use cannabis (marijuana) and cannabis products to manage symptoms during chemotherapy or immunotherapy. The goal is to learn about the benefits and risks so doctors can better guide patients.
Beavercreek, OhioAges 18 years+ - NCT03556228RecruitingPhase 1/Phase 2
Tested medicine for tumors with TrkA changes, alone or with pembrolizumab
This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.
Maumee, OhioAges 18–80
Lymphoma trials by city in Ohio
Where these studies are running in Ohio
Institutions with a site for the recruiting lymphoma studies listed above.
- The Ohio State University · 8 studies
- Cleveland Clinic · 3 studies
- University of Cincinnati · 3 studies
- Cincinnati Children's Hospital Medical Center · 2 studies
- Nationwide Children's Hospital · 2 studies
- Oncology Hematology Care · 2 studies
- University Hospitals Cleveland Medical Center · 2 studies
- Armes Family Cancer Center
What taking part in a lymphoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Lymphoma trials in other states
Common questions
- Are there lymphoma clinical trials in Ohio?
- Yes. We're currently tracking 130 recruiting lymphoma studies with a site in Ohio, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lymphoma study in Ohio?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Ohio to take part?
- Not necessarily. These studies have a site in Ohio, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lymphoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lymphoma studies open in Ohio regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.